Form 4: Precision BioSciences Director Equity Vesting

Director Shari Lisa Pire acquired 21,000 shares of Precision BioSciences common stock following the vesting of restricted stock units.

Summary

• Director Shari Lisa Pire exercised and vested 21,000 restricted stock units (RSUs) on May 20, 2026.
• The transaction resulted in the acquisition of 21,000 shares of common stock.
• Following this transaction, the reporting person holds a total of 35,028 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard equity compensation vesting rather than a strategic shift or market-moving financial development.

Positives

• Director alignment with company equity through the vesting of long-term incentive awards.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• None identified; this is a standard regulatory disclosure of equity compensation.

Future Outlook

Not applicable; this is a historical disclosure of an equity transaction.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance and executive compensation practices within the biotechnology sector, where equity-based incentives are common for board members.

Comparison to Industry Standards

• The vesting of RSUs for board members is consistent with standard compensation practices for publicly traded biotech companies.
• The reporting of this transaction via Form 4 complies with SEC Section 16(a) requirements.

Stakeholder Impact

• Minimal impact on shareholders as this represents the fulfillment of existing compensation agreements.

Next Steps

• No future actions specified in this filing.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Equity Compensation, Director Ownership